Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $103.72 million. The enterprise value is -$131.99 million.
Important Dates
The last earnings date was Wednesday, March 5, 2025, after market close.
Earnings Date | Mar 5, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 82.98 million shares outstanding. The number of shares has increased by 8.39% in one year.
Current Share Class | 82.98M |
Shares Outstanding | 82.98M |
Shares Change (YoY) | +8.39% |
Shares Change (QoQ) | +0.16% |
Owned by Insiders (%) | 0.43% |
Owned by Institutions (%) | 62.75% |
Float | 82.62M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.31 |
Forward PS | 18.43 |
PB Ratio | 0.80 |
P/TBV Ratio | 0.77 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.26.
Current Ratio | 3.75 |
Quick Ratio | 3.71 |
Debt / Equity | 0.26 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.10% and return on invested capital (ROIC) is -53.82%.
Return on Equity (ROE) | -98.10% |
Return on Assets (ROA) | -35.52% |
Return on Invested Capital (ROIC) | -53.82% |
Return on Capital Employed (ROCE) | -90.38% |
Revenue Per Employee | $131,358 |
Profits Per Employee | -$963,793 |
Employee Count | 246 |
Asset Turnover | 0.08 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.27% in the last 52 weeks. The beta is 1.87, so Editas Medicine's price volatility has been higher than the market average.
Beta (5Y) | 1.87 |
52-Week Price Change | -83.27% |
50-Day Moving Average | 1.51 |
200-Day Moving Average | 2.98 |
Relative Strength Index (RSI) | 41.56 |
Average Volume (20 Days) | 2,455,442 |
Short Selling Information
The latest short interest is 17.44 million, so 21.02% of the outstanding shares have been sold short.
Short Interest | 17.44M |
Short Previous Month | 17.09M |
Short % of Shares Out | 21.02% |
Short % of Float | 21.11% |
Short Ratio (days to cover) | 1.74 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $32.31 million and -$237.09 million in losses. Loss per share was -$2.88.
Revenue | 32.31M |
Gross Profit | -166.93M |
Operating Income | -238.92M |
Pretax Income | -193.45M |
Net Income | -237.09M |
EBITDA | -233.11M |
EBIT | -238.92M |
Loss Per Share | -$2.88 |
Full Income Statement Balance Sheet
The company has $269.91 million in cash and $35.03 million in debt, giving a net cash position of $234.88 million or $2.83 per share.
Cash & Cash Equivalents | 269.91M |
Total Debt | 35.03M |
Net Cash | 234.88M |
Net Cash Per Share | $2.83 |
Equity (Book Value) | 134.27M |
Book Value Per Share | 1.62 |
Working Capital | 212.09M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$210.28 million and capital expenditures -$8.83 million, giving a free cash flow of -$219.11 million.
Operating Cash Flow | -210.28M |
Capital Expenditures | -8.83M |
Free Cash Flow | -219.11M |
FCF Per Share | -$2.64 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -739.37% |
Pretax Margin | -733.72% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -8.39% |
Shareholder Yield | -8.39% |
Earnings Yield | -230.43% |
FCF Yield | -212.95% |
Analyst Forecast
The average price target for Editas Medicine is $8.08, which is 546.40% higher than the current price. The consensus rating is "Buy".
Price Target | $8.08 |
Price Target Difference | 546.40% |
Analyst Consensus | Buy |
Analyst Count | 14 |
Revenue Growth Forecast (5Y) | -10.02% |
EPS Growth Forecast (5Y) | -13.97% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -6.26 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -6.26 |
Piotroski F-Score | 1 |